Takeda's exclusive distribution of Pfizer products in Japan
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Japan Inc. ("Pfizer") announced that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products
Roche employees in 52 countries walk to raise funds to support vulnerable children worldwide
- Details
- Category: Roche
Over 20,000 employees of Roche from 113 Roche sites marked the International Day of the African Child by walking and collecting donations for children in need as part of the 9th Roche Children's Walk.
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved PerjetaTM (pertuzumab). Perjeta is approved in combination with Herceptin® (trastuzumab) and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
JDRF and Novo Nordisk establish R&D collaboration in type 1 diabetes
- Details
- Category: Novo Nordisk
To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease.
Lilly expands strategic partnership with Chinese manufacturer Novast
- Details
- Category: Eli Lilly and Company
In support of its commitment to maximize growth opportunities in China, Eli Lilly and Company (NYSE: LLY) announced an increase of its network of manufacturing capabilities in this key emerging market country through an expanded collaboration with Novast Laboratories, LTD.
Novartis drug Gilenya® shows long-term efficacy and safety
- Details
- Category: Novartis
New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment[1].
Bristol-Myers Squibb Foundation announces $6 million in grants
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation has announced $6 million in additional grants through its Together on Diabetes™ initiative that will help more adults living with type 2 diabetes better manage their disease and make behavioral changes that can improve their overall health.
More Pharma News ...
- Abbott presents phase 3 study results for investigational use of HUMIRA® (Adalimumab)
- ORENCIA® (abatacept) demonstrates comparable efficacy to Humira® (adalimumab)
- Trastuzumab emtansine (T-DM1) reduced the risk of cancer worsening or death
- Boehringer Ingelheim expands development capacities with new technical centre
- UCB expands in Brazil
- Genzyme recognizes World MS Day
- Bristol-Myers Squibb announces global collaboration with leading academic institutions